LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 2833

Search options

  1. Article: Face to face. Interview by Adam Legge.

    Kelly, S / Nelson, J

    Nursing times

    1998  Volume 94, Issue 13, Page(s) 42–43

    MeSH term(s) Career Choice ; Humans ; Job Description ; Nurses/psychology ; Occupational Health Nursing/organization & administration
    Language English
    Publishing date 1998-04
    Publishing country England
    Document type Interview
    ZDB-ID 391202-4
    ISSN 0954-7762 ; 0029-6589
    ISSN 0954-7762 ; 0029-6589
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Developmental expression of metalloproteases ADAM 9, 10, and 17 becomes restricted to divergent pancreatic compartments.

    Asayesh, Amir / Alanentalo, Tomas / Khoo, Nelson K S / Ahlgren, Ulf

    Developmental dynamics : an official publication of the American Association of Anatomists

    2005  Volume 232, Issue 4, Page(s) 1105–1114

    Abstract: The A Disintegrin And Metalloprotease (ADAM) family of metalloproteases affects a variety ... in the pancreatic ductal epithelium. Altogether, the dynamic expression profile of the ADAM proteases described here ... We have analyzed the expression patterns of ADAMs 9, 10, and 17 during pancreas ontogeny. All ADAMs ...

    Abstract The A Disintegrin And Metalloprotease (ADAM) family of metalloproteases affects a variety of proteins with important roles in development and disease, including growth factors and adhesion molecules. We have analyzed the expression patterns of ADAMs 9, 10, and 17 during pancreas ontogeny. All ADAMs investigated were expressed in the pancreatic anlagen but invariably became restricted to divergent pancreatic compartments. ADAM9 and 17 became restricted to the insulin-producing beta-cells and all islet cells, respectively. During embryogenesis, ADAM10 was detected predominantly in acinar cells, but in the adult, it was localized to the cell surface membrane of both endocrine and exocrine cells. In addition to ADAM9, a potential prognostic factor for ductal cancers, we describe the expression of ADAM10 and ADAM17 in the pancreatic ductal epithelium. Altogether, the dynamic expression profile of the ADAM proteases described here may reflect a functional divergence of these as mediators of pancreas biology.
    MeSH term(s) Animals ; Female ; Gene Expression Regulation, Developmental/physiology ; Islets of Langerhans/cytology ; Islets of Langerhans/embryology ; Male ; Metalloendopeptidases/biosynthesis ; Mice ; Mice, Inbred CBA ; Organ Specificity/physiology
    Chemical Substances Metalloendopeptidases (EC 3.4.24.-)
    Language English
    Publishing date 2005-04
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1102541-4
    ISSN 1097-0177 ; 1058-8388
    ISSN (online) 1097-0177
    ISSN 1058-8388
    DOI 10.1002/dvdy.20259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: The identification of seven metalloproteinase-disintegrin (ADAM) genes from genomic libraries.

    Poindexter, K / Nelson, N / DuBose, R F / Black, R A / Cerretti, D P

    Gene

    1999  Volume 237, Issue 1, Page(s) 61–70

    Abstract: Metalloproteinase-disintegrins (ADAMs) are membrane-spanning multi-domain proteins containing ... analysis of all known ADAMs indicates that the zinc-binding motif in the catalytic domain arose ...

    Abstract Metalloproteinase-disintegrins (ADAMs) are membrane-spanning multi-domain proteins containing a zinc metalloproteinase domain and a disintegrin domain which may serve as an integrin ligand. Based on a conserved sequence within the disintegrin domain, GE(E/Q)CDCG, seven genes were isolated from a human genomic library. Two of these genes lack introns and show testis-specific expression (ADAM20 and ADAM21), while the other two genes contain introns (ADAM22 and ADAM23) and are expressed predominantly in the brain. In addition, three pseudogenes were isolated; one of which evolved from ADAM21. Human chromosomal mapping indicated that ADAM22 and ADAM23 mapped to chromosome 7q21 and 2q33, respectively, while the three pseudogenes 1-2, 3-3, and 1-32 mapped to chromosome 14q24.1, 8p23, and 14q24.1, respectively. An ancestral analysis of all known ADAMs indicates that the zinc-binding motif in the catalytic domain arose once in a common ancestor and was lost by those members lacking this motif.
    MeSH term(s) ADAM Proteins ; Amino Acid Motifs ; Amino Acid Sequence ; Animals ; Base Sequence ; Chromosomes, Human ; Conserved Sequence ; Disintegrins/genetics ; Evolution, Molecular ; Genomic Library ; Humans ; Introns ; Membrane Proteins ; Metalloendopeptidases/genetics ; Metalloendopeptidases/metabolism ; Molecular Sequence Data ; Nerve Tissue Proteins/genetics ; Oligonucleotides/genetics ; Phylogeny ; Pseudogenes ; Sequence Homology, Amino Acid
    Chemical Substances Disintegrins ; Membrane Proteins ; Nerve Tissue Proteins ; Oligonucleotides ; ADAM Proteins (EC 3.4.24.-) ; ADAM20 protein, human (EC 3.4.24.-) ; ADAM21 protein, human (EC 3.4.24.-) ; ADAM22 protein, human (EC 3.4.24.-) ; Adam23 protein, mouse (EC 3.4.24.-) ; Metalloendopeptidases (EC 3.4.24.-)
    Language English
    Publishing date 1999-09-03
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 391792-7
    ISSN 1879-0038 ; 0378-1119
    ISSN (online) 1879-0038
    ISSN 0378-1119
    DOI 10.1016/s0378-1119(99)00302-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression.

    Cerretti, D P / DuBose, R F / Black, R A / Nelson, N

    Biochemical and biophysical research communications

    1999  Volume 263, Issue 3, Page(s) 810–815

    Abstract: Metalloproteinase-disintegrins (ADAMs) are type 1 transmembrane proteins that contain a unique ... of all known mammalian ADAMs indicates that the zinc-binding motif in the catalytic domain arose ...

    Abstract Metalloproteinase-disintegrins (ADAMs) are type 1 transmembrane proteins that contain a unique domain structure including a zinc-binding metalloproteinase domain. We have isolated cDNAs encoding two novel members of this family, ADAM29 and ADAM30 which show testis-specific expression. Three forms of ADAM29 were found that encode proteins of 820, 786 and 767 amino acids. All of the amino acid differences are located in the cytoplasmic domain. Two forms of ADAM30 were isolated that encode proteins of 790 and 781 amino acids, with the difference in the coding region occurring in the cytoplasmic domain. ADAM29 and ADAM30 map to human chromosome 4q34 and 1p11-13, respectively. An ancestral analysis of all known mammalian ADAMs indicates that the zinc-binding motif in the catalytic domain arose once in a common ancestor and was subsequently lost by those members lacking this motif.
    MeSH term(s) ADAM Proteins ; Amino Acid Sequence ; Animals ; Cell Membrane/metabolism ; Chromosome Mapping ; Chromosomes, Human ; Cloning, Molecular ; Cytoplasm/metabolism ; DNA, Complementary ; Disintegrins/chemistry ; Disintegrins/metabolism ; Evolution, Molecular ; Female ; Gene Library ; Humans ; Male ; Mammals ; Membrane Proteins/genetics ; Membrane Proteins/isolation & purification ; Metalloendopeptidases/chemistry ; Metalloendopeptidases/genetics ; Metalloendopeptidases/isolation & purification ; Mice ; Molecular Sequence Data ; Organ Specificity ; Phylogeny ; Recombinant Proteins/biosynthesis ; Recombinant Proteins/chemistry ; Recombinant Proteins/isolation & purification ; Sequence Alignment ; Sequence Homology, Amino Acid ; Testis/metabolism
    Chemical Substances DNA, Complementary ; Disintegrins ; Membrane Proteins ; Recombinant Proteins ; ADAM Proteins (EC 3.4.24.-) ; ADAM29 protein, human (EC 3.4.24.-) ; ADAM30 protein, human (EC 3.4.24.-) ; Metalloendopeptidases (EC 3.4.24.-)
    Language English
    Publishing date 1999-10-05
    Publishing country United States
    Document type Journal Article
    ZDB-ID 205723-2
    ISSN 0006-291X ; 0006-291X
    ISSN (online) 0006-291X
    ISSN 0006-291X
    DOI 10.1006/bbrc.1999.1322
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Managing hypercholesterolaemia.

    Nelson, Adam J / Nicholls, Stephen J

    Australian prescriber

    2024  Volume 47, Issue 1, Page(s) 7–14

    Abstract: Hypercholesterolaemia is one of the most common conditions treated by clinicians in Australia. Low-density lipoprotein cholesterol (LDL-C) plays a causal role in the development and progression of atherosclerosis and cardiovascular disease. Every 1 mmol/ ... ...

    Abstract Hypercholesterolaemia is one of the most common conditions treated by clinicians in Australia. Low-density lipoprotein cholesterol (LDL-C) plays a causal role in the development and progression of atherosclerosis and cardiovascular disease. Every 1 mmol/L reduction in LDL-C concentration is associated with a 21 to 25% reduction in the relative risk of prospective atherosclerotic cardiovascular events, and emerging evidence suggests this benefit increases over time. Absolute cardiovascular risk assessment identifies patients likely to derive the most benefit from lowering LDL-C concentration, and helps determine the intensity of their treatment regimens and targets. Optimal management of LDL-C may require combination treatment with multiple classes of drugs.
    Language English
    Publishing date 2024-02-20
    Publishing country Australia
    Document type Journal Article ; Review
    ZDB-ID 1075442-8
    ISSN 0312-8008
    ISSN 0312-8008
    DOI 10.18773/austprescr.2024.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Catalytic machinery of enzymes expanded.

    Nelson, Adam

    Nature

    2019  Volume 570, Issue 7760, Page(s) 172–173

    MeSH term(s) Catalysis ; Enzymes/metabolism
    Chemical Substances Enzymes
    Language English
    Publishing date 2019-06-03
    Publishing country England
    Document type News ; Comment
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/d41586-019-01596-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Reply: Low Asian Enrollment in Cardiometabolic Studies and the Importance of Trial Context.

    Nelson, Adam J / Azzopardi, Robert / Lam, Carolyn S P / Nicholls, Stephen J

    JACC. Asia

    2024  Volume 4, Issue 4, Page(s) 343

    Language English
    Publishing date 2024-02-27
    Publishing country United States
    Document type Journal Article
    ISSN 2772-3747
    ISSN (online) 2772-3747
    DOI 10.1016/j.jacasi.2024.01.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Simple Bayesian models for missing binary outcomes in randomized controlled trials.

    Kaplan, Adam / Nelson, David

    Statistics in medicine

    2023  Volume 42, Issue 24, Page(s) 4377–4391

    Abstract: Missing outcomes are commonly encountered in randomized controlled trials (RCT) involving human subjects and present a risk for substantial bias in the results of a complete case analysis. While response rates for RCTs are typically high there is no ... ...

    Abstract Missing outcomes are commonly encountered in randomized controlled trials (RCT) involving human subjects and present a risk for substantial bias in the results of a complete case analysis. While response rates for RCTs are typically high there is no agreed upon universal threshold under which the amount of missing data is deemed to not be a threat to inference. We focus here on binary outcomes that are possibly missing not at random, that is, the value of the outcome influences its possibility of being observed. Salient information that can assist in addressing these missing outcomes in such situations is the anticipated response rate in each study arm; these can often be anticipated based on prior research in similar populations using similar designs and outcomes. Further, in some areas of human subjects research, we are often confident or we suspect that response rates among RCT participants with successful treatment outcomes will be at least as great as those among participants without successful treatment outcomes. In other settings we may suspect the opposite relationship. This direction of the differential response between those with successful and unsuccessful outcomes can further aid in addressing the missing outcomes. We present simple Bayesian pattern-mixture models that incorporate this information on response rates to analyze the relationship between a binary outcome and an intervention while addressing the missing outcomes. We assess the performance of this method in simulation studies and apply this method to the results of an RCT of a smoking abstinence intervention.
    Language English
    Publishing date 2023-08-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 843037-8
    ISSN 1097-0258 ; 0277-6715
    ISSN (online) 1097-0258
    ISSN 0277-6715
    DOI 10.1002/sim.9866
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024: Focus on Blood Pressure and Lipids.

    Abrahams, Timothy / Nicholls, Stephen J / Nelson, Adam J

    The Medical clinics of North America

    2024  Volume 108, Issue 3, Page(s) 441–453

    Abstract: Hypertension and dyslipidemia are 2 highly prevalent and modifiable risk factors in patients with stable ischemic heart disease. Multiple lines of evidence demonstrate that lowering blood pressure and low-density lipoprotein cholesterol improves clinical ...

    Abstract Hypertension and dyslipidemia are 2 highly prevalent and modifiable risk factors in patients with stable ischemic heart disease. Multiple lines of evidence demonstrate that lowering blood pressure and low-density lipoprotein cholesterol improves clinical outcomes in patients with ischemic heart disease. Accordingly, clinical guidelines recommend intensive treatment targets for these high-risk patients. This article summarizes the pathophysiology, supporting evidence, and treatment recommendations for management of hypertension and dyslipidemia among patients with manifest ischemic heart disease and points to future research and unmet clinical needs.
    MeSH term(s) Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Blood Pressure ; Risk Factors ; Cholesterol, LDL/therapeutic use ; Hypertension/drug therapy ; Myocardial Ischemia/drug therapy ; Dyslipidemias/drug therapy
    Chemical Substances Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Cholesterol, LDL
    Language English
    Publishing date 2024-01-16
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 215710-x
    ISSN 1557-9859 ; 0025-7125
    ISSN (online) 1557-9859
    ISSN 0025-7125
    DOI 10.1016/j.mcna.2023.12.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Improving medication adherence in cardiovascular disease.

    Nelson, Adam J / Pagidipati, Neha J / Bosworth, Hayden B

    Nature reviews. Cardiology

    2024  

    Abstract: Non-adherence to medication is a global health problem with far-reaching individual-level and population-level consequences but remains unappreciated and under-addressed in the clinical setting. With increasing comorbidity and polypharmacy as well as an ... ...

    Abstract Non-adherence to medication is a global health problem with far-reaching individual-level and population-level consequences but remains unappreciated and under-addressed in the clinical setting. With increasing comorbidity and polypharmacy as well as an ageing population, cardiovascular disease and medication non-adherence are likely to become increasingly prevalent. Multiple methods for detecting non-adherence exist but are imperfect, and, despite emerging technology, a gold standard remains elusive. Non-adherence to medication is dynamic and often has multiple causes, particularly in the context of cardiovascular disease, which tends to require lifelong medication to control symptoms and risk factors in order to prevent disease progression. In this Review, we identify the causes of medication non-adherence and summarize interventions that have been proven in randomized clinical trials to be effective in improving adherence. Practical solutions and areas for future research are also proposed.
    Language English
    Publishing date 2024-01-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2490375-9
    ISSN 1759-5010 ; 1759-5002
    ISSN (online) 1759-5010
    ISSN 1759-5002
    DOI 10.1038/s41569-023-00972-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top